(CTNM) Contineum Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •

CTNM: Neuroscience, Inflammation, Immunology

Contineum Therapeutics, Inc. (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oral small molecule therapies targeting high unmet needs in neuroscience, inflammation, and immunology. The companys lead candidate, PIPE-791, is a brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R), currently in development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). PIPE-791s ability to cross the blood-brain barrier positions it as a promising candidate for central nervous system (CNS) disorders. Additionally, the company is advancing PIPE-307, a selective M1 receptor inhibitor, for depression and relapse-remitting MS, and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, rebranded from Pipeline Therapeutics, Inc. in November 2023, has been operational since its incorporation in 2009 and is headquartered in San Diego, California. The companys strategic focus on CNS and inflammatory diseases aligns with growing demand for innovative therapies in these areas.

Ticker Symbol: CTNM Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Pharmaceuticals

3-month forecast: Based on and , CTNM is expected to face near-term volatility. The stock is currently trading below its 20, 50, and 200-day moving averages, indicating a downtrend. With an average volume of 52,887 shares over 20 days, liquidity remains low, which could amplify price swings. The ATR of 0.68 suggests moderate volatility. On the fundamental side, the companys negative return on equity (-16.87%) and high P/B ratio (2.27) signal elevated risk. However, the market capitalization of $493.12M reflects investor confidence in its pipeline. Investors should monitor clinical trial progress and potential catalysts, as positive developments could drive upside. The lack of forward P/E and P/S highlights the speculative nature of the stock, typical for early-stage biotech companies.

Additional Sources for CTNM Stock

CTNM Stock Overview

Market Cap in USD 166m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2024-04-05

CTNM Stock Ratings

Growth 5y -40.2%
Fundamental -61.6%
Dividend 0.0%
Rel. Strength Industry -56.5
Analysts 4.5/5
Fair Price Momentum 5.44 USD
Fair Price DCF 12.15 USD

CTNM Dividends

No Dividends Paid

CTNM Growth Ratios

Growth Correlation 3m -94.5%
Growth Correlation 12m -54.5%
Growth Correlation 5y -54.5%
CAGR 5y -55.38%
CAGR/Max DD 5y -0.77
Sharpe Ratio 12m -1.42
Alpha -67.41
Beta 1.94
Volatility 65.36%
Current Volume 27.4k
Average Volume 20d 42.4k
What is the price of CTNM stocks?
As of March 14, 2025, the stock is trading at USD 7.14 with a total of 27,400 shares traded.
Over the past week, the price has changed by +10.87%, over one month by -7.15%, over three months by -49.11% and over the past year by -55.38%.
Is Contineum Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Contineum Therapeutics (NASDAQ:CTNM) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -61.57 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTNM as of March 2025 is 5.44. This means that CTNM is currently overvalued and has a potential downside of -23.81%.
Is CTNM a buy, sell or hold?
Contineum Therapeutics has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy CTNM.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CTNM stock price target?
According to ValueRays Forecast Model, CTNM Contineum Therapeutics will be worth about 6.4 in March 2026. The stock is currently trading at 7.14. This means that the stock has a potential downside of -10.22%.
Issuer Forecast Upside
Wallstreet Target Price 29.3 309.7%
Analysts Target Price 28.7 301.5%
ValueRay Target Price 6.4 -10.2%